Scarica l'app Stockscreener
0.701
3.88%
0.0262
Dopo l'orario di chiusura:
.76
0.059
+8.42%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SCYX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.6748
Aprire:
$0.68
Volume 24 ore:
110.62K
Relative Volume:
0.87
Capitalizzazione di mercato:
$34.52M
Reddito:
$135.87M
Utile/perdita netta:
$72.20M
Rapporto P/E:
0.4937
EPS:
1.42
Flusso di cassa netto:
$45.09M
1 W Prestazione:
-5.41%
1M Prestazione:
-19.89%
6M Prestazione:
-42.07%
1 anno Prestazione:
-64.05%
Intervallo 1D:
$0.672
$0.73
Intervallo di 1 settimana:
$0.66
$0.7748
Portata 52W:
$0.66
$2.29
Scynexis Inc Stock (SCYX) Company Profile
Nome
Scynexis Inc
Settore
Telefono
201-884-5485
Indirizzo
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Confronta SCYX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
0.701 | 34.52M | 135.87M | 72.20M | 45.09M | 1.42 |
|
RGC
Regencell Bioscience Holdings Ltd
|
14.60 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.19 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.35 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.37 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.64 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-01-22 | Iniziato | Guggenheim | Buy |
| 2021-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-11 | Aggiornamento | Needham | Hold → Buy |
| 2018-06-27 | Iniziato | Maxim Group | Buy |
| 2017-10-24 | Iniziato | Guggenheim | Buy |
| 2017-07-10 | Iniziato | ROTH Capital | Buy |
| 2017-05-09 | Downgrade | Needham | Buy → Hold |
| 2017-03-03 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-20 | Iniziato | H.C. Wainwright | Buy |
| 2016-10-07 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2016-10-03 | Ripresa | Brean Capital | Buy |
| 2016-08-17 | Iniziato | Guggenheim | Buy |
| 2016-08-09 | Reiterato | Needham | Buy |
| 2016-08-09 | Aggiornamento | WBB Securities | Speculative Buy → Buy |
| 2016-03-28 | Iniziato | Brean Capital | Buy |
| 2015-12-29 | Iniziato | WBB Securities | Speculative Buy |
| 2015-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2015-06-10 | Iniziato | Needham | Buy |
| 2014-05-29 | Iniziato | Canaccord Genuity | Buy |
| 2014-05-29 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Scynexis Inc Borsa (SCYX) Ultime notizie
Millennium Management LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Squarepoint Ops LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Jane Street Group LLC Buys New Holdings in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) & SCYNEXIS (NASDAQ:SCYX) Head-To-Head Survey - Defense World
Northern Trust Corp Has $186,000 Stake in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Scynexis resumes dosing in Phase III MARIO study after lengthy delay - MSN
SCYNEXIS resumes Phase 3 antifungal study after FDA lift By Investing.com - Investing.com South Africa
SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold - Insider Monkey
Scynexis resumes patient dosing in Phase 3 MARIO study - TipRanks
SCYNEXIS Resumes Patient Dosing In Phase 3 MARIO Study - marketscreener.com
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study | SCYX St - GuruFocus
GSK Involved in SCYNEXIS's Phase 3 Study Milestone Dispute | GSK Stock News - GuruFocus
SCYNEXIS resumes Phase 3 antifungal study after FDA lift - Investing.com Australia
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study | SCYX Stock News - GuruFocus
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study - The Manila Times
SCYNEXIS Restarts Critical Phase 3 Trial for Life-Threatening Infection, Faces $30M GSK Payment Battle - Stock Titan
SCYNEXIS Faces Challenges Amidst Antifungal Developments - TipRanks
Biosergen taps antifungal expert as board member - Biostock
FDA lifts hold on Scynexis trial; Incyte’s Zynyz notches another FDA approval - Endpoints News
SCYNEXIS (NASDAQ:SCYX) Now Covered by Analysts at StockNews.com - Defense World
SCYNEXIS Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Scynexis: Q1 Earnings Snapshot - CT Insider
SCYX Reports Strong Q1 Revenue, Progress in Clinical Trials | SCYX Stock News - GuruFocus
SCYX: Cash Reserves and Debt Repayment Update | SCYX Stock News - GuruFocus
SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update | SCYX Stock News - GuruFocus
SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
SCYNEXIS INC SEC 10-Q Report - TradingView
Sector Update: Health Care Stocks Fall Late Afternoon - marketscreener.com
News - Biostock
SCYNEXIS (SCYX) Projected to Post Earnings on Wednesday - Defense World
JPMorgan Chase & Co. Makes New Investment in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
SCYNEXIS, Inc. (NASDAQ:SCYX) Shares Sold by LPL Financial LLC - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
StockNews.com Begins Coverage on SCYNEXIS (NASDAQ:SCYX) - Defense World
GSK 'well positioned' for potential tariffs after beating forecasts - marketscreener.com
Aspergillosis Market Expected to Rise by 2034, Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, - Barchart.com
SCYNEXIS (NASDAQ:SCYX) Upgraded by StockNews.com to Hold Rating - Defense World
Blastomycosis Treatment Market Overall Study Report 2025-2032 | Janssen, Scynexis Inc, Novartis AG, Marck & Co. - openPR.com
Second-Generation Antifungal Aims to Address Invasive Fungal Disease - ContagionLive
Acute Vulvovaginal Candidiasis Treatment Market Poised - openPR.com
SCY-247 shows promise against resistant fungal infections By Investing.com - Investing.com South Africa
SCY-247 shows promise against resistant fungal infections - Investing.com
Breakthrough: SCYNEXIS's New Antifungal Drug Defeats 171 Resistant Fungal Strains in Latest Tests - Stock Titan
Aspergillosis Market on Track for Major Expansion by 2034, According to DelveInsight | F2G, Pulmatrix, TFF Pharmaceuticals, Scynexis, Pulmocide - The Globe and Mail
SCYNEXIS (NASDAQ:SCYX) Lowered to Sell Rating by StockNews.com - Defense World
SCYNEXIS (SCYX) to Release Earnings on Thursday - Defense World
Research Analysts Issue Forecasts for SCYNEXIS FY2029 Earnings - Defense World
StockNews.com Downgrades SCYNEXIS (NASDAQ:SCYX) to Sell - Defense World
SCYNEXIS Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
SCYNEXIS Reports 2024 Financial Results and Updates - TipRanks
Scynexis Inc Azioni (SCYX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.05%
0.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):